Durvalumab
- TRADE NAME: Imfinzi (AstraZeneca)
- INDICATIONS: Locally advanced or metastatic urothelial carcinoma in patients having disease progression following platinum-containing chemotherapy
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Immune checkpoint inhibitor, Monoclonal antibody, Programmed death-ligand (PD-L1) inhibitor
- HALF-LIFE: 17 days
FDA APPROVAL DATE: 05/01/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:PREGNANCY CATEGORY: N/A
Can cause fetal harm
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of durvalumab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/13/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric